Stoxline posted a NEUTRAL today, upgraded from lower rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.
Ohr Pharmaceutical beats by $0.03
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018
OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ohr Pharmaceutical, Inc. To Contact The Firm
OHRP EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018
Lifshitz & Miller LLP Announces Investigation of BioScrip, Inc., Civitas Solutions, Inc., Iridex Corp., OHR Pharmaceutical, Inc., Overstock.com, Inc., Syneos Health, Inc., Ubiquiti Networks, Inc. and WageWorks, Inc.
The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018 (OHRP)
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Ohr Pharmaceutical, Inc. to Contact the Firm